Summary
Introduction
Little is known about how to optimize resuscitation for patients with out-of-hospital cardiac arrest. This is evident from the very low survival rates that are currently reported. [1] [2] [3] The advent of automatic external defibrillators (AEDs) and their potential for wide-spread use by less highly trained emergency medical service (EMS) providers and lay persons has not resulted in the substantial increased survival rates anticipated. 4 This has led to speculation that sooner and better circulation of oxygenated blood to the brain and heart may be important, even with AED availability.
The Resuscitation Outcomes Consortium (ROC) was created to evaluate the treatment of people with out-ofhospital cardiac arrest or life-threatening injury. 5 ROC is conducting a large randomized trial that uses a partial factorial design to test two strategies to increase blood flow during CPR. One strategy involves the impedance threshold device (ITD) (Figure 1a-d) . This device enhances venous return and cardiac output by increasing the degree of negative intrathoracic pressure during decompression. It also increases coronary perfusion pressure so as to enhance delivery of oxygenated blood to the heart. The second strategy involves initiating resuscitation with a several minute period of manual compressions and ventilations before rhythm analysis (Analyze Later), rather than attempting defibrillation with a briefer period of manual compressions and ventilations (Analyze Early). Both strategies will be implemented concurrently in similar patient populations. The purpose of this paper is to describe the rationale and methods for the assessment of the impedance threshold device. The rationale and methods for the assessment of Analyze Later versus Analyze Early are described in a companion paper.
Background and significance
The ITD is based on the principle that creating a greater negative intrathoracic pressure on the upstroke of CPR leads to increased venous blood return to the heart and increased cardiac output. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Compared with standard CPR, improved hemodymanics with use of the ITD is dependent on the quality of CPR provided [19] [20] [21] [22] [23] [24] [25] and the degree of chest wall recoil. 26, 27 This concept has been evaluated in animals 6, 7, [9] [10] [11] 15, 17 as well as in human patients with prolonged cardiac arrest undergoing standard manual CPR. [28] [29] [30] The first controlled animal study of the ITD with standard CPR used a 4-min period of cardiac arrest followed by standard CPR with an automated compression device. 15 Standard CPR was performed with and without the ITD in an alternating fashion. Each time the ITD was removed from the respiratory circuit, the coronary perfusion pressures and vital organ perfusion decreased; each time the ITD was added back, perfusion pressures stabilized or increased.
A similar study evaluated active ITD versus sham ITD for 11 min after a 6-min period of cardiac arrest without CPR. 6 A sham ITD was used in the control group and an active ITD in the other. After 6 min of cardiac arrest and 6 min of standard CPR, radiolabeled microspheres were injected to measure vital organ blood flow. The active ITD increased left ventricular flow by 100%, and nearly normalized blood flow to the brain compared to the sham ITD.
After a total of 17 min of ventricular fibrillation and 11 min of CPR, 3/11 pigs in the sham ITD group and 6/11 pigs in the active ITD group were resuscitated by direct current shock. In many ways, this 6-min arrest time prior to start of CPR more closely resembles clinical field experience where the time from arrest to the start of CPR in the United States ranges from 4 to 8 min in cities with highly efficient EMS systems.
A recent human study randomized 230 adults with outof-hospital cardiac arrest to receive standard CPR and sham ITD versus standard CPR and active ITD. 28, 29 The primary outcome of this study was admittance to ICU. 28 Femoral arterial blood pressures were also evaluated during standard CPR at the scene in 22 other patients using the same protocol. 29 ICU admissions for all patients were not significantly different with use of the active ITD versus sham ITD (25% vs. 17%, respectively, P = NS). However, there were significantly increased ICU admissions in patients presenting in pulseless electrical activity (PEA) with use of active ITD, 19% (5 of 26) versus 52% (14 of 27) (P = 0.02; not significant when corrected for comparisons in three rhythm groups .05/3 = .017) (Figure 2 ). In the hemodynamic study, systolic blood pressure was significantly increased with the active ITD versus the sham ITD: 85.1 ± 28.9 mmHg (n = 10) versus 42.9 ± 15.1 mmHg (n = 12), respectively; P < 0.001 ( Figure 3) .
The ITD in combination with conventional manual CPR was evaluated in a case-control study in large EMS system in Staffordshire, England. 30 Survival to emergency department admittance was significantly greater among patients with any initial rhythm who received the ITD (61/181 [34%]) compared with historical controls (180/808 [22%]) (P < 0.01). No device-related adverse effects were observed.
In summary, these studies demonstrate that the ITD improves hemodynamics and short-term outcomes. A large trial is now required to demonstrate whether the ITD signifi- Figure 1 Description of impedance threshold device. The ITD (a) is designed to be inserted easily between a facemask or advanced airway (e.g., ET tube, Combitube, or LMA) and a manual resuscitation bag (b). In addition to an advanced airway, the ITD can be attached to any pediatric or adult facemask (c) taking care to provide a continuously tight seal around the nose and mouth during compressions and ventilations (d). As such, the device can be easily used by rescuers trained at both basic and advanced life support levels and moved quickly from any facemask once the patient is intubated. The ITD contains ventilation timing assist lights, which flash at 10 min −1 at 1 s/flash, to help promote the proper ventilation rate and duration for the patient with an advanced airway. For this trial, ITDs will be specially manufactured in an opaque color so that active (functional) and sham (non-functional placebo) devices will appear externally identical. cantly improves survival to hospital discharge and functional status.
Aims
The primary aim of the trial is to compare survival to hospital discharge with a modified Rankin score (MRS) ≤ 3 between standard CPR plus active ITD versus standard CPR plus sham ITD in patients with out-of-hospital cardiac arrest.
Secondary aims are to compare survival to discharge, functional status scores at discharge and at 1, 3 and 6 months as well as depression at 3 and 6 months between standard CPR plus active ITD versus standard CPR plus sham ITD in patients with out-of-hospital cardiac arrest.
Materials and methods

Study design
This study qualifies for waiver of consent in emergency research as outlined in the United States by FDA regulation 21CFR50.24 and in Canada by the Tri-Council Agreement for research in emergency health situations (Article 2.8).
This randomized trial will evaluate manual CPR with either an active or sham ITD in adult patients with out-ofhospital cardiac arrest. Randomization will occur through use of a study ITD that is constructed such that the sham and active valves are indistinguishable. 
Study episodes
Episodes attended by EMS will be included if a study device was taken from its sealed container. All such episodes will be followed for purposes of safety evaluation.
Study population
Included will be persons aged 18 years or more (or local age of consent) who suffer non-traumatic cardiopulmonary arrest outside of the hospital in the study communities who receive defibrillation and/or chest compressions by EMS providers dispatched to the scene. The etiology will be presumed to be non-traumatic in origin unless the apparent cause is due to blunt, penetrating or burn related injury, drowning, strangulation, electrocution, or exsanguination.
Excluded will be persons with 'do not attempt resuscitation' (DNAR) orders; trauma; known prisoners; known pregnancy; persons bearing a designated indicator (e.g., bracelet) of their having ''opted out'' of the trial as required by local IRBs; tracheostomy; CPR performed with any mechanical compression device; ventilated with a mechanical device (e.g., automated transport ventilator); or initial treatment by a non-ROC EMS agency/provider with no agreement in place to obtain relevant EMS data.
Comparison populations
The ITD is conjectured to provide an improvement in the rate of neurologically intact (MRS ≤ 3) survival to hospital discharge in those patients experiencing out-of-hospital cardiac arrest (OOHCA) of cardiac origin and treated by EMS within 15 min of initial call to 911. There is, however, no known contraindication to the use of the ITD in the relatively few patients for whom the cardiac origin of OOHCA cannot be accurately determined, and such patients may be included in the clinical trial to contribute safety information.
Efficacy population
Analysis of primary and secondary efficacy outcomes will be conducted on a modified intent-to-treat basis. In order to be included in these analyses, patients must meet the inclusion/exclusion criteria for the ITD/sham device intervention. Furthermore, they must have had a response time from call received at 911 dispatch to arrival at the scene of less than 15 min, and had the ITD actually applied.
Safety population
Evaluation of the safety of the ITD will be made using all data from patients who were treated with a device, regardless of whether they are a member of the efficacy population.
Intervention
The intervention will be implemented by the first qualified ROC provider to arrive at the scene of cardiac arrest and continued by subsequent providers in all ROC sites. Upon arrival of EMS providers at a patient with cardiac arrest, CPR will be initiated. Defibrillation will be performed consistent with local practice and cluster assignment (see companion paper). For subjects who are being ventilated with bag-mask or advanced airway (e.g., combitube, laryngeal mask airway [LMA], or endotracheal tube), EMS providers will insert an ITD between the bag and the mask/airway. The ITD is constructed in a manner (male connection to the mask/airway or advanced airway, and female connection to the ventilation bag/apparatus) that prevents its proper orientation to the patient from being inadvertently reversed. Training will target use of the ITD with initial management of the airway to assure the earliest placement of the ITD during CPR. To assure correct ventilation rate, the rescuers will turn on the ventilation timing assist lights on the device once an advanced airway has been established. The providers will be instructed to immediately remove the ITD if the patient has return of spontaneous circulation or is breathing spontaneously (to facilitate rapid elimination of inspiratory impedance in a resuscitated patient). The study ITD has a safety check valve that opens if the pressure in the airway is <16 cm H 2 O in the event the rescuer does not recognize spontaneous respirations. The providers will be instructed to immediately reapply the ITD if such a patient has recurrent cardiac arrest.
If the ITD fills with fluid, the EMS providers will be instructed to disconnect the ITD, removing the fluid by forcing air through the device, suction the patient, and reapply the ITD. If the ITD fills with fluid a second time, the ITD will be permanently removed. Use of the ITD will be discontinued on arrival to the hospital. All other resuscitative measures will follow individual EMS agency standard operating procedures.
Random allocation
Study devices will be randomly allocated in a proportion of 1:1 active versus sham, with distribution determined by the coordinating center based on permuted blocks of concealed size within strata defined by participating site and within site by participating agency or subagency. Devices will be packaged with a flexible connector to facilitate adjunct equipment such as CO 2 monitoring. A mask will also be provided to facilitate achievement of a good seal between the patient's face and the ventilatory circuit so as to maintain the intrathoracic pressure. Each ITD package will be identifiable by a coded number, which will be recorded on the emergency care record. Active and sham ITDs look identical. Patients will be considered randomized if the ITD package is opened. If two bags are opened during the arrest episode, the patient will be assigned to the treatment group of the bag opened by the first-arriving vehicle.
Training
The training objectives for the ITD study include: review of optimal CPR performance, scientific basis for and review of the study protocol, practicum/''hands-on'' session, and post-test, requiring approximately 2 h of didactic instruction and 1 h of practicum. Supplemental web-based training materials will also be available for initial training or retraining. Some type of retraining will occur at least every 6 months. Initial and retraining performance criteria include: correct assembly of the airway, time to ITD application <30 s, continuously tight seal maintained during compressions and ventilations when ITD is used with a facemask, ventilation timing lights turned on following placement of an advanced airway, immediate removal of ITD with return of spontaneous circulation, immediate reapplication of the ITD with re-arrest, and clear or remove ITD if it fills with fluid.
Run-in phase
After personnel have been trained in use of the ITD, sites will initiate a run-in phase. Evidence of compliance with the protocol and completion and submission of the data will be required before the site can enroll in the active phase of the trial.
Monitoring protocol compliance
A monitoring committee will evaluate protocol compliance during the run-in and active phases of the trial. Guidelines include: ITDs should be placed on 90% of ITD eligible patients, interval from ROC-ITD vehicle arrival to placement of ITD is <5 min for 90% of analyzable cases, providers should report a continuously tight facemask seal during compressions and ventilations when the ITD is used with a bag-valve-mask, and there should be no inappropriate enrollment or treatment of subjects. Compliance will be further monitored by tracking the incidence of not using the ITD with a facemask (ITD use with advanced airway only) , opening a bag but not using the ITD, and opening more than one ITD bag/patient.
Performance of high quality CPR is considered essential to the success of any intervention during resuscitation. Accordingly, all participating EMS agencies have implemented a high-quality system for monitoring individual components of CPR, to include the rate of chest compressions, the rate of ventilation, and the proportion of pulseless resuscitation time during which chest compressions are provided (i.e. CPR fraction) as described in the companion paper.
Expected adverse events
The following will be considered adverse events if they occur during the resuscitative effort or the hospital stay:
Pulmonary edema: The presence of pulmonary edema in patients who survive long enough to receive a hospital-based chest X-ray (first emergency department or ICU chest Xray) will be evaluated. Because pulmonary congestion in the immediate aftermath of cardiac arrest is not an unexpected finding, its incidence will be monitored in each treatment arm. Similarly, in the out-of-hospital setting, all incidences where the valve fills with fluid will be reported.
Device failure: Any instances of device malfunctions will be reported.
Other: Vomiting during CPR is a common and anticipated complication of any method of CPR and its occurrence will be monitored in each treatment arm. Clinical diagnoses of cerebral bleeding, stroke, seizures, bleeding requiring transfusion or surgical intervention, recurrent cardiac arrest, serious rib fractures, sternal fractures, internal thoracic or abdominal injuries as well as any other major medical or surgical outcomes will be collected from the hospital discharge summary.
Notably, death or neurological impairment of an individual patient is not considered an adverse event in this study.
Results
Primary
The primary analysis of treatment efficacy will be based on a comparison across treatment arms (active and sham ITD) of the observed proportion of patients in the efficacy popula-tion with neurologically intact (MRS ≤ 3) survival to hospital discharge.
Secondary
The secondary outcomes are MRS at 3 and 6 months following hospital discharge; adult lifestyle and function (ALFI) version of the mini-mental status exam (MMSE) at 1, 3 and 6 months; 31, 32 as well as Health Utilities Index III (HUI3) score 33 and geriatric depression scale (T-GDS) 34 score at 3 and 6 months. All secondary analyses of efficacy outcomes are directed toward finding supporting evidence for the findings of the primary efficacy analysis. Hence, there is no plan to make any statistical adjustment for the multiple comparisons inherent in the secondary efficacy analyses.
In-hospital morbidity
Number of hospital days and time interval from 911 call to patient death will be described for all hospitalized patients as measures of morbidity after resuscitation. Analyses will be performed in each subgroup, along with tests for statistically significant interactions. However, it is recognized that the study is not powered adequately to detect interactions, and thus all subgroup analyses will be of an exploratory nature.
Prespecified subgroup analyses
Sample size and study duration
The potential benefit of the ITD to increase neurologically intact survival is hypothesized to vary according to presenting cardiac rhythm from 20.2% to 24.2% in VT/VF, from 4.20% to 5.88% in PEA, and from 1.05% to 1.47% in asystole. Any potential benefit of the ITD is hypothesized to be greatest when it is used as early as practicable, which might be prior to determination of the prior rhythm. The study is therefore powered to detect the differences that would be observed in a population that included 25% VT/VF, 25% PEA, and 50% asystole.
Based on a one-sided significance level of 0.025, power = 0.90, a survival with MRS ≤ 3 to discharge rate of 5.32% with standard CPR and sham ITD, and two interim analyses, a maximum of 14,742 evaluable patients are needed to detect a 6.68% survival with MRS ≤ 3 to discharge with standard CPR and active ITD (1.36% absolute survival difference). The study will require approximately 16-18 months of enrollment.
Conclusion
A large clinical trial is needed to determine the impact of the ITD on survival to hospital discharge and functional outcome for patients with cardiac arrest. Preliminary data indicates the ITD has potential to have substantial impact. If the ITD demonstrates the hypothesized improvement in survival, we estimate that the premature demise of approximately 2700 victims of cardiac arrest 1 per year would be averted in North America compared to standard CPR without use of the ITD.
